Biotech, Food & Drug

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization
Mar
28
2024
EC Publishes Communication on Biotechnology and Biomanufacturing, Announces Targeted Actions Bergeson & Campbell, P.C.
Mar
27
2024
New Biden Executive Order Emphasizes Women’s Health Mintz
Mar
27
2024
Federal Circuit Applies Safe Harbor to Imported Medical Device Samples Foley & Lardner LLP
Mar
27
2024
FTC Releases Report on Infant Formula Market Keller and Heckman LLP
Mar
27
2024
Arizona Attorney General Deems Delta-8 and Delta-10 Controlled Substances in Controversial Opinion Bradley Arant Boult Cummings LLP
Mar
27
2024
Connecticut Appellate Court Rules Employer Could Discharge Medical Marijuana User Impaired on the Job Ogletree, Deakins, Nash, Smoak & Stewart, P.C.
Mar
26
2024
CODEX ALIMENTARIUS: Outcome of 28th Codex Committee on Fats and Oils (CCFO28) Keller and Heckman LLP
Mar
26
2024
Recent Bankruptcy Court Decision Leaves the Door Open to Bankruptcy Relief for Those in the Cannabis Industry Mintz
Mar
26
2024
Effective April 1, California’s ‘Fast Act’ Covers More Than ‘Fast Food,’ Comes with Significant Implications Greenberg Traurig, LLP
Mar
26
2024
Gerber Explains Vitamin C Not Used as a Preservative in Baby Snacks Keller and Heckman LLP
Mar
26
2024
Last Call for Comments on the Bipartisan Discussion Draft of the SUSTAIN Act: Shaping 340B for the Future Epstein Becker & Green, P.C.
Mar
26
2024
Delta’s Rough Waters: Attorneys General Call for Regulation of ‘Intoxicating Hemp Products’ Norris McLaughlin P.A.
Mar
26
2024
Court Clarifies Employers’ Rights Under Connecticut’s Palliative Use of Marijuana Act, Guidance on Drug Testing Epstein Becker & Green, P.C.
Mar
26
2024
President Biden Announces New Price Fixing “Strike Force”: Government Continues Antitrust Crusade Proskauer Rose LLP
Mar
25
2024
OECD Issues Report on First WPMN Workshop on NanoCarriers Bergeson & Campbell, P.C.
Mar
25
2024
Pardon? Massachusetts Cannabis Offenders Given New Hope Bradley Arant Boult Cummings LLP
Mar
25
2024
The Price Is “Wrong”: SEC Sanctions Pharma Company for Faulty Rebates Norris McLaughlin P.A.
Mar
25
2024
PFAS in Food Packaging: The Beginning of the End? Sheppard, Mullin, Richter & Hampton LLP
Mar
22
2024
Pennsylvania Proposes to Ban Certain Food Additives Keller and Heckman LLP
Mar
22
2024
HHS and FDA Seek Comments on Informed Consent Draft Guidance McDermott Will & Emery
Mar
22
2024
NNI Will Hold Webinar on Metrology of Nanoparticles in Electronics on April 5, 2024 Bergeson & Campbell, P.C.
Mar
22
2024
Duplicating with Digital Twins: Two Peas in a Pod One Real, One Virtual Nishith Desai Associates
Mar
22
2024
A Moving Target: Recent New Jersey Case Shows Changing Laws Complicate Cannabis Business Norris McLaughlin P.A.
Mar
21
2024
FDA Announces End of PFAS Use in US Food Packaging Squire Patton Boggs (US) LLP
Mar
21
2024
A Psychedelic Use Case for AI Nelson Mullins
Mar
21
2024
FDA Publishes Paper Detailing Actions It Intends to Take Regarding the Uses of AI Across the Medical Product Life Cycle Nelson Mullins
Mar
21
2024
Specially Convened Rehearing Panel Vacates IPR Institution Denial McDermott Will & Emery
Mar
21
2024
Legalizing LSD? FDA Says Mm-hmm to MM120 Bradley Arant Boult Cummings LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins